MedTrace Logo

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

NCT01251835 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-03-05

No results posted yet for this study

Summary

This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.

Conditions

Interventions

DRUG

Sitaxsentan alone

Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)

DRUG

Sitaxsentan

Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)

DRUG

Rifampin

Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-01-31
Completion
2011-01-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01251835 on ClinicalTrials.gov